MTF Biologics and Kolosis BIO Launch Summit Matrix™ to Advance Orthopedic and Spinal Surgery Outcomes
MTF Biologics, a global nonprofit dedicated to saving and healing lives through tissue and organ donation, transplantation, and medical research, has partnered with Kolosis BIO (Kolosis), a leading provider of orthobiologic solutions, to announce the launch of Summit Matrix™—a next-generation synthetic bone graft engineered to enhance bone regeneration in orthopedic and spinal surgeries. The new graft integrates NanoLift™ surface technology, which combines nanoscale topography, biomimetic chemistry, and superior handling characteristics to optimize surgical performance and improve patient outcomes.
“MTF Biologics was founded nearly 40 years ago by orthopedic surgeons with a mission to develop solutions that advance patient care,” said Brad Bailey, Vice President and General Manager of MTF Biologics’ Orthopedic Franchise. “Summit Matrix continues this legacy by representing a significant advancement in bone graft technology. We are proud to expand our collaboration with Kolosis BIO through this innovation. Together, we are providing solutions that streamline surgical procedures and enhance clinical practice.”
Summit Matrix™: A Leap in Bone Graft Technology
Summit Matrix signifies an important evolution in the orthobiologic offerings from MTF Biologics and Kolosis, complementing their existing portfolio, which includes Kore Fiber®, Prime HD®, DBX® Mix, and DBX® Putty. The graft features NanoLift’s nanocrystalline, plate-like surface, designed to support cellular activity essential for new bone formation. Its hydroxycarbanoapatite composition closely mimics the mineral structure of natural bone, promoting optimal resorption and osseointegration. This biomimetic approach helps surgeons achieve reliable and predictable fusion outcomes, while also offering the handling characteristics that facilitate precision during complex procedures.
“Kolosis has quickly established itself as a leader in the orthobiologics space, particularly in spine and orthopedic surgery,” said Collin Begley, CEO of Kolosis BIO. “We are excited to introduce Summit Matrix to our growing portfolio. With the combined expertise of Kolosis and MTF Biologics, we can provide surgeons and healthcare providers a best-in-class offering that integrates synthetic ceramics with allograft tissues—all through a single, trusted partner.”
The launch of Summit Matrix reflects a broader trend in orthopedic surgery toward advanced biomaterials that not only replace lost or damaged bone but also actively promote regeneration. By leveraging nanoscale surface technology and a chemically optimized matrix, Summit Matrix supports cell attachment, proliferation, and differentiation, ultimately helping surgeons restore skeletal integrity more efficiently.
MTF Biologics: Advancing Patient Care Through Innovation
MTF Biologics operates globally as a nonprofit organization with a mission to save and heal lives by honoring donated gifts and advancing medical science. In collaboration with organ and tissue recovery organizations, MTF Biologics provides comprehensive services, resources, and expertise to donors and their families, transplant patients, and clinicians who rely on tissue for patient care.
The organization also includes divisions such as:
- The International Institute for the Advancement of Medicine (IIAM), which utilizes non-transplantable organs for research, supporting the development of new therapies and the fight against disease.
- Statline, which delivers specialized screening, coordination, and communication services to organ transplant centers, tissue and eye procurement organizations, hospitals, and patients.
- DIZG (Deutsches Institute für Zell-und Gewebeersatz), MTF Biologics’ sister organization in Germany, which expands its global reach to improve patient access to high-quality tissue and transplantation solutions.
Through these efforts, MTF Biologics continues to combine scientific innovation with a commitment to donor honor, ethical tissue management, and advancing healthcare standards.
Source link : https://www.businesswire.com/
